- Home
- Daily Diary
- Asset Class
- Sector
- Latest
- Author
- Street Notes
- TheStreet
- Switch to
- Premium Tools
- Real Money
- Real Money Pro
- Action Alerts PLUS
- Stocks Under $10
- Breakout Stocks
- Options Profits
Latest Commentary
Real Money: Independent market insight from a veteran team of trusted Wall Street pros.
• Up-to-the-minute reports on market activity
• Actionable trade ideas
• Up-to-the-minute reports on market activity
• Actionable trade ideas
Latest Strategies
Real Money Pro: Professional tools and specific trade ideas for active investors.
• Information-packed market flow providing trade ideas, fast
• Dynamic interface with professional-grade analytical tools
• Full, unlimited access to Real Money
• Information-packed market flow providing trade ideas, fast
• Dynamic interface with professional-grade analytical tools
• Full, unlimited access to Real Money
Latest Alert
May 22, 2013 | 10:35 AM EDT
Well buy this industrial on a pullback and build our position in a healthcare stock. FULL ALERT »
Action Alerts PLUS: Jim Cramer and Stephanie Link actively manage a real money portfolio for Jim's charitable trust.
• Timely trade alerts including price targets
• Unique insight into market movements
• Guidance on how to trade right alongside Jim and Stephanie
• Timely trade alerts including price targets
• Unique insight into market movements
• Guidance on how to trade right alongside Jim and Stephanie
Latest Alert
May 22, 2013 | 10:27 AM EDT
The stock has doubled over the past three months and we don't want to be greedy with our gains. FULL ALERT »
Stocks Under $10: David Peltier manages a portfolio of affordable stocks with huge upside potential.
• Identify fast-growing small-cap stock opportunities
• Buy and sell alerts allow you to analyze overlooked opportunities quickly
• In-depth reports and research packed with proprietary analysis
• Identify fast-growing small-cap stock opportunities
• Buy and sell alerts allow you to analyze overlooked opportunities quickly
• In-depth reports and research packed with proprietary analysis
Latest Alert
May 22, 2013 | 02:54 PM EDT
We are advantage of the market weakness to buy more shares of this holding. We are also bumping up our rating on the stock. FULL ALERT »
Breakout Stocks: Bryan Ashenberg, CFA, manages a portfolio of small and mid-cap stocks with high growth potential.
• Identify industry-changing macrotrends in their infancy
• Timely trade alerts loaded with detailed research
• Frequent communication about all Bryan's portfolio holdings
• Identify industry-changing macrotrends in their infancy
• Timely trade alerts loaded with detailed research
• Frequent communication about all Bryan's portfolio holdings
Latest Commentary
Options Profits: Day in and day out, our team of professional options traders search for inventive plays for trading spikes in market activity, emerging trends, and breaking news and events. These veterans reveal all their charts and technical data — delivering daily strategies and insightful commentary written specifically for the options trader plus 40 options trade ideas per week!
Express Scripts (ESRX)
ESRX (NASDAQ:Health Services)
$62.32
+1.02
+1.66%
Today's Range: 61.10 - 63.38 |
ESRX Avg Daily Volume: 5,376,900
| Last Update: 05/22/13 - 3:16 PM EDT |
| Volume: 6,808,932 |
| YTD Performance: 13.57% |
| Open: $61.47 |
| Previous Close: $61.31 |
| 52 Week Range: $49.79 - $66.06 |
| Oustanding Shares: 817,529,000 |
| Market Cap: 50,139,053,570 |
Analysts Ratings
| Historical Rec | Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago |
|---|---|---|---|---|
| Strong Buy | 10 | 9 | 11 | 12 |
| Moderate Buy | 3 | 3 | 3 | 3 |
| Hold | 2 | 3 | 4 | 3 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.43 | 1.57 | 1.58 | 1.47 |
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
Average Earnings Estimates
| Qtr (06/13) | Qtr (09/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $1.10 | $1.09 | $4.30 | $4.94 |
| Number of Analysts | 11 | 10 | 12 | 13 |
| High Estimate | $1.13 | $1.11 | $4.32 | $5.15 |
| Low Estimate | $1.09 | $1.07 | $4.28 | $4.75 |
| Prior Year | $0.88 | $1.02 | $3.74 | $4.30 |
| Growth Rate (Year over Year) | 25.31% | 6.57% | 14.91% | 14.97% |
DrugStockNews: Is it time to #buy or #sell.Check out the recent trades $VOD $ESRX $WIN $RIG $YHOO $IAL http://t.co/MqPNKIB64y
52 minutes ago from web
52 minutes ago from web
quorumreview: RT @FiercePharma: Specialty drugs shift into hyperdrive with 67% growth by 2015, Express Scripts says http://t.co/NgezwA2SRK #pharma $ESRX
2 hours ago from web
2 hours ago from web
FiercePharma: Specialty drugs shift into hyperdrive with 67% growth by 2015, Express Scripts says http://t.co/NgezwA2SRK #pharma $ESRX
2 hours ago from TweetDeck
2 hours ago from TweetDeck
CROSSHAIRTRADER: $ESRX firing an ITCH and heading to 65 on the weekly? http://t.co/ItqlDqjbZa
3 hours ago from StockTwits Web
3 hours ago from StockTwits Web
tradingview: $ESRX chart by @flavisam: http://t.co/Cc3HSbemhB express scripts.
5 hours ago from TradingView
5 hours ago from TradingView
OracleofWallSt: Shopping list of stock picks for long-term holdings: $ACN, $ACGL, $AME, $BUD, $EMN, $ESRX, $MON, $PETM, $TJX, $WFC. Of these like $ACN most.
19 hours ago from web
19 hours ago from web
KV_crazy: Via @themotleyfool - OTCs and then Some - $CVS, $ESRX, $WAG - http://t.co/Vam3f9YLqV @WalgreensNews keep it up!
23 hours ago from Tweet Button
23 hours ago from Tweet Button
micenter: Potential Express Scripts $ESRX Trade Has $59.85 Breakeven ( http://t.co/6kL2geEZzY )
1 day ago from Marketintelligencecenter.com
1 day ago from Marketintelligencecenter.com
JStockton_12: Buying the buyers & transformative #mna has been a nice theme. $CBI got some run due to $BRKA filing, but another candidate is $ESRX.
1 day ago from web
1 day ago from web
A normally reliable short-term indicator looks bearish.
Express Scripts upgraded at Jefferies
ESRX was upgraded from Hold to Buy, Jefferies said. $74 price target. Uncertainty is gone and the company should resume share repurchases.
Express Scripts numbers increased at BMO
ESRX estimates were raised through 2014, BMO Capital said. Company continues to execute on its plan. Market Perform rating and new $62 price target.
Express Scripts and McKesson could both see weakness.
For Walgreen, 2012's bad news was good news, while CVS remains an attractive investment choice.
Express Scripts numbers upped at Citi
ESRX estimates were boosted through 2014, Citigroup said. Company is keeping a tight lid on costs. Buy rating and new $64 price target.
These two solid names are finding support at their longer-term moving averages.
Express Scripts numbers boosted at Lazard
Shares of ESRX now seen reaching $65, according to Lazard Capital Markets. Estimates also upped, given better operating trends. Buy rating.
It’s much tougher to actually “buy low to sell high” than it is to espouse the concept.
ESRX still has a a historically low valuation.
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.
TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.
IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.
TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.
IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.
© 2013 TheStreet, Inc. All rights reserved.